SYRE Kronos AI forecast
A 30-trading-day price forecast for Spyre Therapeutics Inc. (SYRE) from Kronos AI, an open-source foundation model trained on candlestick charts.
Kronos AI's median forecast puts Spyre Therapeutics Inc. at $88.28 on 2026-12-08, −10.9% from the last close of $99.04 on 2026-10-27. Eight out of ten sampled paths end between $79.79 and $97.01, and 0 of the 8 paths finish above today's price.
Forecast path
median, with the 10–90% band of the sampled pathsOpen the interactive forecast → Full analysis of SYRE
The forecast, week by week
| Date | Median | Low (10%) | High (90%) |
|---|---|---|---|
| 2026-11-03 | $102.36 | $93.29 | $105.89 |
| 2026-11-10 | $96.34 | $92.26 | $99.38 |
| 2026-11-17 | $92.40 | $88.73 | $102.29 |
| 2026-11-24 | $94.52 | $87.80 | $100.93 |
| 2026-12-01 | $99.34 | $87.40 | $102.24 |
| 2026-12-08 | $88.28 | $79.79 | $97.01 |
What is Kronos AI?
Kronos is an open-source foundation model for financial candlesticks, pre-trained on K-line data from more than 45 exchanges. Gnzub runs it on each stock's last 120 daily bars and samples several possible futures, so the forecast is a range of outcomes rather than one confident line. It is a statistical model, not an analyst: it reads price patterns only and knows nothing about news, earnings or the business.
Questions
- What is the Kronos AI forecast for SYRE?
- Kronos AI's median forecast for SYRE is $88.28 in 30 trading days, −10.9% from the last close, with a 10–90% range of $79.79 to $97.01.
- Is the SYRE Kronos forecast a buy or sell signal?
- No. It is the output of a statistical model that reads price history only. It is not investment advice, and the range shows how uncertain the model is.
- How often is the forecast updated?
- The forecasts are regenerated regularly; this one starts from the close of 2026-10-27.
Kronos forecasts for similar companies
- LLY — Eli Lilly and Company
- JNJ — Johnson & Johnson
- ABBV — AbbVie Inc.
- MRK — Merck & Company Inc.
- NVS — Novartis AG
- AZN — AstraZeneca PLC